Progressive multifocal leukoencephalopathy in the era of new disease-modifying treatments for multiple sclerosis

被引：0
|
作者：
Filippi-Arriaga, Francesca [1 ]
Riera-Arnau, Judit [1 ]
Rodriguez-Acevedo, Breogan [2 ]
Bosch Ferrer, Montserrat [1 ]
机构：
[1] Univ Autonoma Barcelona, Serv Farmacol Clin, Hosp Univ Vall Hebron, Barcelona, Spain
[2] Univ Autonoma Barcelona, Unitat Neuroinmunol Clin, Ctr Esderosi Multiple Catalunya Cemcat,Serv Neuro, Vall Hebron Inst Recerca VHIR,Hosp Univ Vall Hebr, Barcelona, Spain
来源：
MEDICINA CLINICA | 2021年 / 156卷 / 10期
关键词：
PML;
D O I：
10.1016/j.medcli.2020.10.015
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：509 / 514
页数：6
相关论文
共 50 条
  • [21] New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis
    Vidal-Jordana, Angela
    [J]. NEUROLOGIC CLINICS, 2018, 36 (01) : 173 - +
  • [22] Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm
    Giovannoni, Gavin
    [J]. CURRENT OPINION IN NEUROLOGY, 2018, 31 (03) : 233 - 243
  • [23] ADHERENCE TO DISEASE-MODIFYING TREATMENTS IN PATIENTS WITH ACTIVE AND NONACTIVE PROGRESSIVE MULTIPLE SCLEROSIS IN THE UNITED STATES
    Chen, J.
    Watson, C.
    Thirumalai, D.
    Barlev, A.
    Jones, E.
    Bogdanovich, S.
    Kresa-Reahl, K.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S333 - S333
  • [24] Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis
    Portaccio, Emilio
    Fonderico, Mattia
    Iaffaldano, Pietro
    Pasto, Luisa
    Razzolini, Lorenzo
    Bellinvia, Angelo
    De Luca, Giovanna
    Ragonese, Paolo
    Patti, Francesco
    Morra, Vincenzo Brescia
    Cocco, Eleonora
    Sola, Patrizia
    Inglese, Matilde
    Lus, Giacomo
    Pozzilli, Carlo
    Maimone, Davide
    Lugaresi, Alessandra
    Gazzola, Paola
    Comi, Giancarlo
    Pesci, Ilaria
    Spitaleri, Daniele
    Rezzonico, Marta
    Vianello, Marika
    Avolio, Carlo
    Logullo, Francesco O.
    Granella, Franco
    Salvetti, Marco
    Zaffaroni, Mauro
    Lucisano, Giuseppe
    Filippi, Massimo
    Trojano, Maria
    Amato, Maria Pia
    [J]. JAMA NEUROLOGY, 2022, 79 (09) : 869 - 878
  • [25] Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
    Morillo Verdugo, Ramon
    Ramirez Herraiz, Esther
    Fernandez-Del Olmo, Raquel
    Roig Bonet, Montserrat
    Valdivia Garcia, Maria
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 261 - 272
  • [26] Disease-modifying treatments for multiple sclerosis - a review of approved medications
    Torkildsen, O.
    Myhr, K. -M.
    Bo, L.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 18 - 27
  • [27] Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis
    Hartung, Hans-Peter
    Meuth, Sven G.
    Miller, Deborah M.
    Comi, Giancarlo
    [J]. CURRENT OPINION IN NEUROLOGY, 2021, 34 (04) : 598 - 603
  • [28] Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis
    Thompson, Joel P.
    Abdolahi, Amir
    Noyes, Katia
    [J]. PHARMACOECONOMICS, 2013, 31 (06) : 455 - 469
  • [29] Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy
    Bartt, Russell E.
    [J]. CURRENT OPINION IN NEUROLOGY, 2006, 19 (04) : 341 - 349
  • [30] Progressive Multifocal Leukoencephalopathy with Natalizumab Treatment of Multiple Sclerosis
    Clifford, David B.
    DeLuca, Andrea
    Simpson, David
    Arendt, Gabriele
    Giovannoni, Gavin
    Nath, Avindra
    [J]. NEUROLOGY, 2010, 74 (09) : A281 - A282
12345